BACKGROUND: Many patients with multiple sclerosis (MS) eligible for beta-interferons or glatiramer acetate have chosen to forgo or discontinue treatment The objective of this study was to evaluate risk attitude as a patient characteristic related to treatment choice for patients with MS. METHODS: Sixty-two MS patients completed a survey on treatment history, risk preference, and socioeconomic and clinical variables. Multinomial logistic regression was used to assess the relationship between treatment choice and risk attitude. Risk attitude was measured using a standard gamble question on short-term health outcomes. RESULTS: More risk-seeking patients were less likely to choose treatment compared with more risk-averse patients (P < 0.01). Forpatients who discontinued treatment, the explanatory variable of significance was severity of side effects (P < 0.05). CONCLUSIONS: Risk attitude is a patient characteristic related to treatment initiation in patients with MS. This could be an important factor to consider when identifying optimal treatment decisions for individual patients.
BACKGROUND: Many patients with multiple sclerosis (MS) eligible for beta-interferons or glatiramer acetate have chosen to forgo or discontinue treatment The objective of this study was to evaluate risk attitude as a patient characteristic related to treatment choice for patients with MS. METHODS: Sixty-two MSpatients completed a survey on treatment history, risk preference, and socioeconomic and clinical variables. Multinomial logistic regression was used to assess the relationship between treatment choice and risk attitude. Risk attitude was measured using a standard gamble question on short-term health outcomes. RESULTS: More risk-seeking patients were less likely to choose treatment compared with more risk-averse patients (P < 0.01). Forpatients who discontinued treatment, the explanatory variable of significance was severity of side effects (P < 0.05). CONCLUSIONS: Risk attitude is a patient characteristic related to treatment initiation in patients with MS. This could be an important factor to consider when identifying optimal treatment decisions for individual patients.
Authors: Kathryn A Atchison; Claudia Der-Martirosian; Thomas R Belin; Edward E Black; Melanie W Gironda Journal: J Oral Maxillofac Surg Date: 2010-08-03 Impact factor: 1.895
Authors: Leslie S Wilson; Aimee Loucks; Gregory Gipson; Lixian Zhong; Christine Bui; Elizabeth Miller; Mary Owen; Daniel Pelletier; Douglas Goodin; Emmanuelle Waubant; Charles E McCulloch Journal: Int J MS Care Date: 2015 Mar-Apr
Authors: Claudia Der-Martirosian; Melanie W Gironda; Edward E Black; Thomas R Belin; Kathryn A Atchison Journal: J Public Health Dent Date: 2010 Impact factor: 1.821